UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) shares gapped down before the market opened on Thursday . The stock had previously closed at $251.34, but opened at $235.10. UCB shares last traded at $235.10, with a volume of 1 shares changing hands.

Analysts Set New Price Targets

A number of research analysts recently weighed in on UCBJF shares. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group raised shares of UCB to a “hold” rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

UCB Stock Down 6.3%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s 50 day moving average price is $270.79 and its 200 day moving average price is $288.60.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.